This Article Full Text (PDF) All Versions of this Article: 0269881106073126v1 21/4/440    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stone, J. M. Articles by Pilowsky, L. S. Search for Related Content PubMed PubMed Citation Articles by Stone, J. M. Articles by Pilowsky, L. S. Social Bookmarking                   What's this?

Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

King's College London Institute of Psychiatry, London, UK, j.stone{at}iop.kcl.ac.uk

Paul D. Morrison

King's College London Institute of Psychiatry, London, UK

Lyn S. Pilowsky

King's College London Institute of Psychiatry, London, UK

The dopamine hypothesis of schizophrenia is the principal explanatory model of antipsychotic drug action. Recent discoveries extend our understanding of the neurochemistry of schizophrenia, with increasing evidence of dysfunction in glutamate and GABA as well as dopamine systems. In this review, we study the evidence for dopaminergic dysfunction in schizophrenia, drawing data from neurochemical imaging studies. We also review the NMDA receptor hypofunction hypothesis of schizophrenia as a supplementary explanatory model for the illness. We examine predictions made by the NMDA receptor hypofunction hypothesis and consider how they fit with current neurochemical findings in patients and animal models. We consider the case for glutamatergic excitotoxicity as a key process in the development and progression of schizophrenia, and suggest ways in which glutamate and dopamine dysregulation may interact in the condition.

Key Words: schizophrenia • gLutamate • NMDA • dopamine • SPECT • PET

This version was published on June 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 4, 440-452 (2007)
DOI: 10.1177/0269881106073126


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. F. Terwisscha van Scheltinga, S. C. Bakker, and R. S. Kahn Fibroblast Growth Factors in Schizophrenia Schizophr Bull, May 8, 2009; (2009) sbp033v1. [Abstract] [Full Text] [PDF]

				M. P. Coba, A. J. Pocklington, M. O. Collins, M. V. Kopanitsa, R. T. Uren, S. Swamy, M. D. R. Croning, J. S. Choudhary, and S. G. N. Grant Neurotransmitters Drive Combinatorial Multistate Postsynaptic Density Networks Sci. Signal., April 28, 2009; 2(68): ra19 - ra19. [Abstract] [Full Text] [PDF]

				P. Niehusmann, J. Dalmau, C. Rudlowski, A. Vincent, C. E. Elger, J. E. Rossi, and C. G. Bien Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy Arch Neurol, April 1, 2009; 66(4): 458 - 464. [Abstract] [Full Text] [PDF]

				T. Takahashi, S. J. Wood, A. R. Yung, B. Soulsby, P. D. McGorry, M. Suzuki, Y. Kawasaki, L. J. Phillips, D. Velakoulis, and C. Pantelis Progressive Gray Matter Reduction of the Superior Temporal Gyrus During Transition to Psychosis Arch Gen Psychiatry, April 1, 2009; 66(4): 366 - 376. [Abstract] [Full Text] [PDF]

				R. C. Welsh, A. C. Chen, and S. F. Taylor Low-Frequency BOLD Fluctuations Demonstrate Altered Thalamocortical Connectivity in Schizophrenia Schizophr Bull, November 5, 2008; (2008) sbn145v1. [Abstract] [Full Text] [PDF]

				P. Harrison, L. Lyon, L. Sartorius, P. Burnet, and T. Lane Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia J Psychopharmacol, May 1, 2008; 22(3): 308 - 322. [Abstract] [PDF]